ANNX
HealthcareAnnexon, Inc.
$5.22
+$0.53 (+11.30%)
Jan 5, 2026
Price History (1Y)
Analysis
Annexon, Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $778.07M and approximately 99 employees. Financially, Annexon, Inc. reported significant losses, with net income of -$208,880,992 (TTM) and EBITDA of -$216,468,000 (TTM). The company's cash balance stands at $188.72M, while debt is recorded at $26.94M. This results in a debt-to-equity ratio of 16.69. Annexon, Inc.'s valuation metrics include a forward P/E of -4.38 and an EV/EBITDA of -1.84. The company's gross margin, operating margin, and profit margin are all reported at 0.0%. Returns on equity (ROE) and assets (ROA) stand at -84.0% and -45.0%, respectively. The current ratio is calculated as 4.42.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Visit website →Key Statistics
- Market Cap
- $778.07M
- P/E Ratio
- N/A
- 52-Week High
- $5.48
- 52-Week Low
- $1.28
- Avg Volume
- 2.62M
- Beta
- 1.19
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 99